title: Fibrinogen concentrate substitution therapy for obstetric hemorrhage complicated by coagulopathy.
abstract: OBJECTIVE
  The aim of this study was to assess the efficacy and safety of fibrinogen concentrate therapy for women with obstetric hemorrhage complicated by dilutional or consumptive coagulopathy by retrospectively reviewing the medical records of relevant patients from a single tertiary center.
  
  
  METHODS
  Eighteen cases of coagulopathy (8 dilutional, 10 consumptive) administered fibrinogen concentrate at our center over the past 5 years for treating hypofibrinogenemia were identified. Hemoglobin levels, platelet counts, fibrinogen levels, prothrombin time, activated partial thromboplastin time, and D-dimer levels were examined before and after fibrinogen substitution. Units of red blood cells, fresh frozen plasma, and pooled platelet concentrates transfused; blood loss volume; patient outcomes; and adverse events were obtained from medical and laboratory records.
  
  
  RESULTS
  The overall response to fibrinogen concentrate was considered good in 12 cases, moderate in four, and poor in two. The response rate was good or moderate in 88% (7/8) of dilutional coagulopathy cases and 89% (9/10) of consumptive coagulopathy cases. Fibrinogen levels significantly increased after fibrinogen substitution therapy (approximately 40 mg/L per g fibrinogen concentrate) in both groups. Although prothrombin time and activated partial thromboplastin time improved after substitution, hemoglobin levels, platelet counts, and D-dimer levels remained unchanged. No serious adverse event was causally associated with fibrinogen substitution therapy.
  
  
  CONCLUSIONS
  Fibrinogen concentrate substitution therapy for obstetric hemorrhage increases fibrinogen levels and appears to be effective in managing dilutional or consumptive coagulopathy.
authors.affiliation: Department of Obstetrics and Gynecology, Saitama Medical University, Saitama, Japan.
authors.forename: Mariko
authors.initials: M
authors.lastname: Kikuchi
authors.forename: Atsuo
authors.initials: A
authors.lastname: Itakura
authors.forename: Akinori
authors.initials: A
authors.lastname: Miki
authors.forename: Manabu
authors.initials: M
authors.lastname: Nishibayashi
authors.forename: Kenji
authors.initials: K
authors.lastname: Ikebuchi
authors.forename: Osamu
authors.initials: O
authors.lastname: Ishihara
mesh_terms: D000328:Adult; D001778:Blood Coagulation Disorders / Q000150:complications*; D001779:Blood Coagulation Factors / Q000009:adverse effects / Q000032:analysis / Q000627:therapeutic use*; D005260:Female; D005340:Fibrinogen / Q000009:adverse effects / Q000032:analysis / Q000627:therapeutic use*; D006490:Hemostatics / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D006801:Humans; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000097:blood / Q000628:therapy*; D012189:Retrospective Studies; D014592:Uterine Hemorrhage / Q000097:blood / Q000150:complications / Q000628:therapy*
chemical_list: D001779:Blood Coagulation Factors; D006490:Hemostatics; D005340:Fibrinogen